# MicroRNA Profiles in Triple Negative Breast Cancer

Source: https://onco.cc/trials/nct04771871/  
OnCo record `nct04771871` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of epirubicin, cyclophosphamide, paclitaxel / nab-paclitaxel and carboplatin in triple-negative breast cancer, run by University College Hospital, Ibadan, now recruiting.

## Summary

MicroRNA Profiles in Triple Negative Breast Cancer is a phase 2, interventional study registered as NCT04771871 by University College Hospital, Ibadan, with a registry enrolment figure of 42 participants, started 2021-11-29 and due to reach its primary completion in 2027-03. Interventions recorded: Epirubicin; Cyclophosphamide; Paclitaxel; Carboplatin. Conditions listed: Triple Negative Breast Cancer. Triple-negative eligibility wording from the registry: "Patients with histologically confirmed carcinoma of the female breast with triple negative status by immuno-histochemistry (IHC)". Sites: Nigeria. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: TARMAC
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT04771871
- Phase: 2
- Setting: Treatment Response and microRNA Profiles in Triple Negative Breast Cancer Patients Receiving Standard Chemotherapy
- Sponsor: University College Hospital, Ibadan
- Enrolled: 42

## Sources

- ClinicalTrials.gov NCT04771871: https://clinicaltrials.gov/study/NCT04771871

## Connected records

- cancers: [Early triple-negative breast cancer](https://onco.cc/cancers/tnbc-early/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Platinum agents](https://onco.cc/technologies/platinum/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Cyclophosphamide](https://onco.cc/drugs/cyclophosphamide/), [Epirubicin](https://onco.cc/drugs/epirubicin/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct04771871.json